RS59004B1 - Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora - Google Patents
Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptoraInfo
- Publication number
- RS59004B1 RS59004B1 RS20190878A RSP20190878A RS59004B1 RS 59004 B1 RS59004 B1 RS 59004B1 RS 20190878 A RS20190878 A RS 20190878A RS P20190878 A RSP20190878 A RS P20190878A RS 59004 B1 RS59004 B1 RS 59004B1
- Authority
- RS
- Serbia
- Prior art keywords
- rod
- endoscope
- optical
- transmission device
- image transmission
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
SNECMA MOTEURS i SNECMA SERVICES
APARAT ZA ISPITIVANJE I PRONALAŽENJE OŠTEĆENJA U DELOVIMA
PUTEM ENDOSKOPIJE
Ovaj pronalazak se odnosi na endoskopski aparat za ispitivanje i pronalaženje oštećenja na delovima koji su po prirodi nedostupni i nalaze se iza pregrade.
STANJE TEHNIKE
Poznato je ispitivanje unutrašnjih delova opreme ili mašina pomoću endoskopa, odnosno jednim izduženim optičkim instrumentom malog prečnika koji je provučen kroz mali otvor u zidu u cilju ispitivanja izgleda komponente koji se nalaze sa druge strane pregrade. To omogućava naročito ispitivanje lopatica turbo mašina kao kod avionskih turbomlaznica ili turbopropelera, bez demontaže turbomašine.
Ipak, mogućnost otkritivanja oštećenja je ograničena rezolucijom optičkog sistema endoskopa, osvetijenjem, usmerenjem endoskopa u odnosu na površinu koja se posmatra, kao i prirodom oštećenja u odnosu na druge predmete.
Takodje je poznato traženje oštećenja na mašinskom komponentama korišćenjem tehnike testa ispunjavanja, koji se sastoji u nanošenju organskih supstanci na površinu komponente koja se ispituje i opažanjem rezultata pod ultraljubičastim osvetijenjem. Stoga je moguće otkriti površinske diskontinuitete kao što su pukotine ili naprsline koje su veoma malih dimenzija i koje su nevidljive pod normalnim osvetljenjem putem nanošenja fluorescentne boje na komponentu koja ispunjava površinske diskontinuitete, a potom pranjem i zagrevanjem ili sušenjem odgovarajuće površine komponente, i istovremenim nanošenjem razvijača kako bi otkrio fluorescentnu boju koja je ispunila površinske diskontinuitete. Komponenta se tada osvetli ultraljubičastim zračenjem koje pobudi ultraljubičastu boju što reaguje emitovanjem zračenja druge talasne dužine, na primer zelenom bojom ili vidljivim spektrom.
Ova tehnike testa ispunjavanja generalno zahteva da mašina koja se ispituje bude, manje ili više, sasvim raskloplj ena.
U dokumentu US-A- 4 273 110 je predloženo rešenje koje kombinuje u jednom instrumentu tehniku endoskopije i test ispunjavanja a sastoji se iz izduženog cilindričnog omotača malog prečnika, kvarcne lampe za prenošenje ultraljubičastog i vidljivog svetla do kraja instrumenta koji se nalazi blizu komponente koja se ispituje, svetlosne cevi koja sadrži sočivo radi zapažanja osvetljene zone komponente, i tri cevi za napajanje i rasprskavanje testa ispunjavanja na komponentu koja se ispituje. Optički filter koji zadržava vidljivo svetio je prenosno montiran na drugi kraj instrumenta izmedju kvarcne lapme i izvora svetlosti koje emituje vidljivo i ultraljubičasto svetio da bi omogućio da komponenta bude alternativno osvetljena vidljivom svetlošću ili ultraljubičastom svetlošću. Spoljni prečnik omotača instrumenta je dovoljno mali da mu omogući da prodje kroz endoskomski otvor i ima prečnik od oko 9 milimetara (mm).
Instrument obuhvaćen stanjem tehnike ima nekoliko nedostataka.
Osvetijavanje komponente ultraljubičastom svetlošću vrši se preko osnog ispusta u cilju izbegavanja upotrebe reflektujućih ogledala koja prekomerno uvećavaju i absorbuju svetlost. Šta više, deo cevi za posmatranje svetlom je previše mali tako da ta cev mora ostaviti dodatnog unutrašnjeg prostora unutar obloge da bi se omogućilo da kvarcna lampi i cev za napajanje i raspršivanje supstance testa ispunjavanja bude instalirana, tako da kada se instrument koristi sa ultraljubičastom svetlošću, on može prikupiti samo mali deo svetla koje emituje supstanca testa ispunjavanja, te stoga ne omogućava da se posmatranje izvrši realno.
PREDMET I SUŠTINA PRONALASKA
Specifičan predmet pronalaska je da omogući rešenje ovog problema koji je jednostavan, zadovoljavajući i j eftin.
Pronalazak nastoji da omogući aparat koji spaja tehnike endoskopije i testa ispunjavanja dok otklanja nedostatke kod poznatih tehnika.
S te strane, pronalazak omogućava aparat za ispitivanje i prolanaženje oštećenja na sastojcima koji su po prirodi nedostupni i nalaze se iza pregrade, koji aparat se sastoji od čvrste cevaste cilindrične šipke malih dimenzija za propuštanje otvora endoskopa u zid, cevi smeštene u šipku za nanošenje supstance testa ispunjavanja na mesto na delu koji se ispituje, svetlovoda i uredjaja za prenos slike smeštenog u šipku kako bi osvetlio i osmotrio to mesto na delu koji se posmatra, pri čemu su svetlovod i uredjaj za prenos slike sačinjeni od prvog endoskopa koji dejstvuje sa vidljivim svetlom montiran aksijalno u šipku i okružen cevima za vazduh i za supstance testa ispunjavanja, gde pomenuti endoskop ima pravolinijsku cev u koju su paralelno smešteni svetlovod i uredjaj za prenos slike, i gde se aparat dalje sastoji od drugog endoskopa koji dejstvuje sa ultraljubičastom svetlošću, nezavisno od prvog endoskopa i gore navedene šipke za posmatranje mesta na delu koji se obradjuje putem supstance testa ispunjavanja.
U aparatu pronalaska nalazi se endoskop vidljivog svetla koji je smešten u cilindrišnu šipku zajedno sa cevi za supstancu testa ispunjavanja, koji se koristi samo za posmatranje vidljivog svetla na mestu na delu na koji je raspršena supstanca testa. Dejstva ove supstance se tada posmatraju pomoću drugog endoskopa čije optičke karakteristike nisu umanjene njegovim poprečnim presekom koji je smanjen zbog prisustva cevi za nanošenje supstance testa i koja je smeštena u cev dimenzija koje su dovoljno male da mu omoguće da prodje kroz endoskopski otvor.
Osvetijavanje mesta na delu koji treba da se obradi vidljivom svetlošću dovoljno je da omogući da supstanca testa bude ispravno naneta, a osvetijavanje tog mesta na delu ultraljubičastom svetlošću putem drugog endoskopa čini mogućim jasno posmatranje dejstava supstance testa, čime se poboljšava otkrivanje oštećenja na delu koji se ispituje.
Prema još jednoj karakteristici pronalaska, svetlovod prvog endoskopa sastoji se od optičkog vlakna koji se pruža od jednog do drugog kraja šipke, koji ima iskrivljen ispust koji je relativno nakošen prema osi šipke i služi za dovodjenje u blizinu mesta na delu koji treba da se ispita.
Otvor za osvetijavanje stoga nije osni, već je vertikalan na osu šipke, na primer, okretanje šipke oko svoje ose i pomeranje pomenute šipke premeštanjem duž svoje ose čini mogućim da se osvetli i posmatra velika površina delova.
Uredjaj za prenos slike prvog endoskopa sastoji se od pravolinijskog kompleta optičkih komponenti koji se sastoji od objektiva za formiranje slike i sočiva za prenos slike, koji komplet se prostire od jednog do drugog kraja šipke i takodje sadrži svetlosni reflektor smešten na kraju pomenutog kompleta komponenti na svojoj optičkoj osi i
relativno je nakošen prema toj optičkoj osi.
Ovaj optički reflektor i kraj iskrivljenog ispusta kabla za osvetijavanje su blizu jedan drugom i usmereni su na odgovarajući način tako da osvetle i osmatraju isto mesto na delu.
Poželjno je da optički reflektor formira prizmu.
Reflektujuća strana prizme je prigodno postavljena na 45° u odnosu na optičku osu uredjaja za prenos slike a iskrivljeni ispist kabla za osvetijavanje se pruža vertikalno na osu šipke.
Cevi koje su položene u šipku oko prvog endoskopa sastoje se od cevi za vazduh, cevi za prah i cevi za tečnost, i pružaju se od jednog do drugug kraja šipke i svaki ima početni kraj za spoj sa uredjajem za napajanje. Drugi krajevi cevi za prah i tečnost imaju otvorene izlaze na odgovarajućim krajevima šipke kao kod uredjaja za osvetijavanje i za prenos slike prvog endoskopa, gde je drugi kraj vazdušne cevi otvoren prema spolja osno prema šipki u cilju zaštite prvog endoskopa i da bi sprečio da prah i tečnost budu naneti na njegovom kraju.
U navedenom sklopu pronalaska, šipka prvog endoskopa ima prečnik od oko 4 milimetra (mm) a cev ima prečnik od oko 8 mm.
Drugi endoskop za osvetijavanje ultraljubičastom svetlošću može imati spoljni prečnik koji je suštinski isti kao kod napred navedene cevi, što obezbedjuje dobre performanse u uslovima osvetljenja ultraljubičastom svetlošću i posmatranje oštećenja na delovima.
KRATAK OPIS CRTEŽA
Pronalazak će se bolje razumeti, a njegove druge karakteristike, detalji i prednosti će izgledati jasnije pri čitanju opisa koji sledi, uz pomoć primera za
obeležjima na priloženim crtežima, gde je:
• Slika 1 šematski prikaz aparata pronalaska za osvetljavanje vidljivom svetlošću i nanošenje supstance testa ispunjavanja na deo koji se ispituje; • Slika 2 šematski prikaz drugog endoskopa za osvetijavanje dela koji se ispituje pod ultraljubičastom svetlošću; • Slike 3 i 4 su šematski prikaz preseka cevi za osvetijavanje vidljivom svetlošću i za nanošenje supstance testa ispunjavanja; i • Slika 5 šematski osni presek endoskopa vidljive svetlosti koji se koristi u toj cevi.
DETALJNI OPIS
Na slici 1 br. 10 označava zid kao što je košuljica turbomašine iza koje se nalazi deo 12 za ispitivanje, kao što je lopatica rotora turbomašine.
Zid 10 sadrži endoskopski otvor 14 malih dimenzija (tipično prečnika od 9 mm) kroz koji je moguće umetnuti cev 16 za osvetijavanje vidljivom svetlošću i za raspršivanje supstance testa ispunjavanja, čiji jedan kraj sadrži deo 18 za vezu sa uredjajem za snabdevanje supstance testa ispunjavanja i komprimovanog vazduha, a njen drugi kraj 2 0 je napravljen tako da prinet prema površini dela 12 koji se ispituj e.
Šipka 16 je detaljnije prikazana na slikama 3 i 4. Šipka je čvrst cevasti cilindar, na primer napravljen od metala, koji se sastoji od prvog endoskopa 22 za osvetljavanje vidljivom svetlošću i posmatranje, cevi 24 za snabdevanje i raspršivanje praha na površinu dela 12 koji treba ispitiati, cevi 26 za snabdevanje komprimovanog vazduha i cevi 28 za snabdevanje i raspršivanje tečnosti koja može biti aceton, ispunjavajućeg agensa, emulgatora i
vode. Prvi endoskop 22 i cevi 24, 26 i 28 uzduž se pružaju u šipku 16 od jednog njenog dela do drugog, endoskop leži na osi šipke 16 a cevi 24, 26 i 28 su rasporedjene oko endoskopa.
Kako je šematski prikazano na slikama 1 i 3, prvi endoskop 22 ima prvi kraj 30 za vezu sa izvorom vidljive svetlosti i drugi kraj koji je dole detaljnije opisan i koji je otvoren na kraju 2 0 šipke 16.
Cevi 24 i 28 za nanošenje supstance testa ispunjavanja imaju prvi kraj 32 za spoj sa posudom 34 koja sadrži supstancu i povezane sa uredjajem za napajanje vazduhom 36, i koje imaju drugi deo 3 8 sa otvorenim izlazom na kraju 2 0 šipke 16 vertikalno u odnosu na osu pomenute šipke.
Uredjaj za napajanje komprimovanim vazduhom i izvor vidljive i ultraljubičaste svetlosti su preporučljivo grupisani zajedno u napajajućem modulu 40, koji obuhvata uredjaj izvora napajanja strujom i izvor napajanja komprimovanim vazduhom.
Kraj 3 0 prvog endoskopa 2 2 uključuje sočivo na koje se gleda okom 42 koje omogućava posmatraču da direktno vidi površinu dela 12 koji se ispituje postavljanjem kraja 20 šipke.
Endoskop 22 je prikazan detaljnije na slici 5, i u osnovi se sastoji od čvrste cilindrične šipke 44, na primer, napravljene od metala unutar koje je smešteno optičko vlakno 46 koje vodi vidljivu svetlost od jednog do drugog kraja endoskopa, kabl 46 ima prvi kraj za spoj sa izvorom vidljive svetlosti koji se nalazi u napajajućem modulu 40, dok je drugi kraj 48 kroz koji se isporučuje svetio produžen, na primer vertikalan na osu šipke 44, do kraja endoskopa koji je udaljen od kraja na kome se nalazi sočivo na koje se gleda okom 42. Uredjaj za prenos slike 50 je takodje smešten unutar šipke 44 i pruža se uzdužno od jednog kraja ka drugom, a uredjaj za prenos slike 5 0 je sačinjen od pravolinijskog sklopa optičkih komponenti i sastoji se naročito od: sočiva objektiva za formiranje slike 52 i jednog ili više prenosnih sočiva 54. Reflektujuće sredstvo 56 smešteno je u šipku 44 blizu sočiva objektiva 52, izmedju pomenutog sočiva i drugog kraja 48 svetlovoda 46, gde optički reflektor 56 formira prizmu koja je smeštena na optičkoj osi uredjaja za prenos slike 50 i koje ima reflektujuću stranu nakošenu za 45° u odnosu na navedenu osu, na primer, u cilju posmatranja u pravcu koji je vertikalan na navedenu optičku osu i paralelan sa pravcem u kom se kraj 48 svetlovoda 46 pruža.
Kao što se jasno može videti na slici 5 svetlovod 46 pruža se pored zida šipke 44 a uredjaj za prenosa slike 50 zauzima uglavnom sav preostali deo šipke, što čini mogućim da se koristi što je moguće veći prostor za prenos slike 50 a u cilju poboljšanja posmatranja.
U navedenom sklopu, datom samo kao primer, čvrsta šipka 44 ima spoljni prečnik od oko 4 mm i dužinu od oko 40 centimetara (cm). Projektovana je da nišani pod uglom od 90° u odnosu na osu i da ima ugao posmatranja od 55°.
Aparat pronalaska sadrži drugi endoskop 60 prikazan šematski na slici 2, koji drugi endoskop je nezavisan od šipke 16 i prvog endoskopa 22 i projektovan je da bude umetnut kroz endoskopski otvor 14 na zidu 10 u cilju posmatranja površine dela 12 pošto je obradjen supstancom testa ispunjavanja.
Ovaj endoskop 60 ima prvi kraj snabdeven sočivom na koje se gleda okom 62 i uredjaj 64 za vezu sa izvorom ultraljubičaste svetlosti koji je deo napajajućeg modula 40, i drugog kraja 66 koji ima svetlosni ispust vertikalan na osu endoskopa za osvetijavanje površine koja je obradjena pomoću dela 20 ultraljubičastom svetlošću i za posmatranj e.
Endoskop 60 može biti uobičajenog tipa ili, preporučljivo, tipa kakav je opisan u drugoj patentnoj prijavi istog prijavioca. Pošto se ovaj endoskop 60 koristi kao samostalan, može imati poprečne dimenzije koje su veće od mogućih ako se koristi zajedno sa ili umesto prvog endoskopa 22 u šipki 16, što uopšteno znači da je moguće bolje osvetliti površinu dela 12 ultraljubičastom svetlošću i bolje posmatrati rezultate testa ispunjavanja.
Aparat pronalaska se koristi kako sledi:
U osnovi, šipka 16 se umetne kroz rupu 14 u zidu 10
i njen kraj 2 0 se pokreće osno okretanjem oko navedene ose, obradjujući površinu 12 kako bi se ispitala.
U cilju potvrde da li je prividno oštećenje dela 12 pravo oštećenje ili nije, kao što je pukotina ili naprslina, supstanca testa ispunjavanja se raspršuje neprekidno na odgovarajuće mesto dela 12, ta supstanca sadrži fluorescentnu tečnost koja ispunjava površinske diskontinuitete, tečnost za pranje i prah za razvijanje za otkrivanje prisustva ispunjavajuće supstance koji je ispunio površinu diskontinuiteta, čak i kada je diskontinuitet veoma malih dimenzija.
Ispitivanje dela 12 i posmatranje raspršivanja supstance testa ispunjavanja na navedeni deo sprovodi se korišćenjem vidljivog svetla kada se površina dela 12 osvetli mlazom svetla koji napušta ugaoni deo 48 svetlovoda 46 na prvom endoskopu, koja svetlost se reflektuje i/ili odbije od površine dela i koju uhvati ogledalo 56 koje je vraća nazad duž ose uredjaja za prenos slike 50 do sočiva na koje se gleda okom 4 2 koje je montirano na drugi kraj prvog endoskopa.
Sipka 16 se tada vadi iz endoskopske rupe 14 i drugi endoskop 60 povezan za izvor ultraljubičaste svetlosti napajajućeg modula 40 se umetne u rupu 14 i njegov kraj 66 se prinese obradjenoj površini na delu 12. Osvetijavanje obradjene površine dela 12 ultraljubičastom svetlošću prouzrokuje da supstance testa ispunjavanja koja je ispunila površinu diskontinuiteta i koja se rasipa i koja je pobudjena razvijačem kada ispunjavajuća supstanca odgovara na to pobudjivanje fluorescentno, na primer sa zelenom bojom, koja se jasno može videti u mraku i koju korisnik može posmatrati pomoću sočiva na koje se gleda okom 62.
Uopšte, prema pronalasku, razdvajanje osvetijavanja sa ultraljubičastim svetlom i osvetijavanja sa vidljivim svetlom čini mogućim da se poboljšaju karakteristike obe operacije osvetijavanja i da se poboljšaju odgovarajući rezultati.
Claims (13)
1. Aparat za ispitivanje i pronalaženje oštećenja na delovima koji su po prirodi nedostupni a koji se nalaze iz zida, koji aparat se sastoji od čvrste cevaste cilindrične šipke malih dimenzija za propuštanje otvora endoskopa u zid, cevi smeštene u šipku za nanošenje supstance testa ispunjavanja na mesto na delu koji se ispituje, svetlovoda i uredjaja za prenos slike smeštenog u šipku da osvetli i osmotri to mesto na delu koji se posmatra, pri čemu je svetlovod i uredjaj za prenos slike sastavljen od prvog endoskopa koji dejstvuje sa vidljivim svetlom i montiran osno u šipku i okružen cevima za vazduh i za supstancu testa ispunjavanja, gde pomenuti endoskop ima pravolinijsku cev u koju su paralelno smešteni svetlovod i uredjaj za prenos slike, i gde se aparat dalje sastoji od drugog endoskopa koji dejstvuje sa ultraljubičastom svetlošću, nezavisno od prvog endoskopa i gore navedene šipke za posmatranje mesta na delu koji se obradjuje putem supstance testa ispunjavanja.
2. Aparat prema zahtevu 1, gde se svetlovod prvog endoskopa sastoji se od optičkog vlakna koji se pruža od jednog do drugog kraja šipke.
3. Aparat prema patentnom zahtevu 2, gde optički kabl ima iskrivljen ispust koji je relativno ukoso usmeren prema osi šipke i služi za dovodjenje u blizinu mesta na delu koji treba da se osvetli vidljivom svetlošću.
4. Aparat prema patentnom zahtevu 1, gde se uredjaj za prenos slike sastoji od pravolinijskog kompleta optičkih komponenti koji se sastoji od objektiva za formiranje slike i sočiva za prenos slike koji se prostire od jednog do drugog kraja šipke.
5. Aparat prema patentnom zahtevu 1, gde se uredjaj za prenos slike prvog endoskopa takodje sastoji od optičkog reflektora smeštenog na kraj šipke na optičkoj osi uredjaja za prenos slike i relativno je ukoso usmeren prema navedenoj osi.
6. Aparat prema patentnom zahtevu 3, gde se uredjaj za prenos slike prvog endoskopa takodje sastoji od optičkog reflektora smeštenog na kraj šipke na optičkoj osi uredjaja za prenos slike i okrenut je relativno ukoso prema navedenoj osi, i gde su optički reflektor i zakrivljeni kraj ispusta optičkog kabla graničnici i usmereni tako da osvetljavaju i osmatraju odredjeno isto mesto na delu.
7. Aparat prema patentnom zahtevu 6, gde je optički reflektor smešten izmedju kraja pravolinijskog kompleta optičkih komponenti i iskrivljenog ispusta optičkog kabla.
8. Aparat prema patentnom zahtevu 5, gde optički reflektor ima oblik prizme.
9. Aparat prema patentnom zahtevu 5, gde optički reflektor ima reflektujuću površinu postavljenu na 45° u odnosu na optičku osu uredjaja za prenos slike a gde se iskrivljeni kraj ispusta kabla pruža vertikalno na osovinu šipke.
10. Aparat prema patentnom zahtevu 2, gde se optički kabl pruža duž zida šipke i gde uredjaj za prenos slike zauzima uglavnom sav preostali deo šipke.
11. Aparat prema patentnom zahtevu 1, gde se cevi koje su položene unutar šipke oko prvog endoskopa sastoje od cevi za vazduh, cevi za prah i cevi za tečnost, i pružaju se od jednog do drugug kraja šipke i svaka ima početni kraj za spoj sa uredjajem za napajanje, gde cevi za prah i trečnost imaju odgovarajuće suprotne krajeve otvorene ka spoljašnosti šipke u istom pravcu kao i uredjaj za osvetijavanje i uredjaj za prenos slike, i gde cev za vazduh ima na suprotnom kraju otvor prema spolja osno prema šipki da bi generisao snop vazduha za zaštitu kraja prvog endoskopa.
12. Aparat prema patentnom zahtevu 1, gde šipka prvog endoskopa ima prečnik od oko 4 mm a navedena šipka ima prečnik od oko 8 mm.
13. Aparat prema patentnom zahtevu 1, gde drugi endoskop za ultraljubičastu svetlost ima spoljni prečnik koji je suštinski identičan onom kod gore navedene šipke.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25450909P | 2009-10-23 | 2009-10-23 | |
| EP16163733.5A EP3093291B1 (en) | 2009-10-23 | 2010-10-21 | Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS59004B1 true RS59004B1 (sr) | 2019-08-30 |
Family
ID=43385633
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20160501A RS54945B1 (sr) | 2009-10-23 | 2010-10-21 | Disupstituisani oktahidropirolo[3,4-c]piroli kao oreksin receptor modulatori |
| RS20190878A RS59004B1 (sr) | 2009-10-23 | 2010-10-21 | Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20160501A RS54945B1 (sr) | 2009-10-23 | 2010-10-21 | Disupstituisani oktahidropirolo[3,4-c]piroli kao oreksin receptor modulatori |
Country Status (38)
| Country | Link |
|---|---|
| US (8) | USRE48841E1 (sr) |
| EP (3) | EP3093291B1 (sr) |
| JP (1) | JP5759470B2 (sr) |
| KR (3) | KR20120105449A (sr) |
| CN (1) | CN102781942B (sr) |
| AR (2) | AR078731A1 (sr) |
| AU (2) | AU2010310595B2 (sr) |
| BR (1) | BR112012010820B1 (sr) |
| CA (1) | CA2778484C (sr) |
| CL (1) | CL2010001162A1 (sr) |
| CO (1) | CO6541572A2 (sr) |
| CR (1) | CR20120273A (sr) |
| CY (2) | CY1117743T1 (sr) |
| DK (2) | DK3093291T3 (sr) |
| EA (1) | EA022766B1 (sr) |
| EC (1) | ECSP12011908A (sr) |
| ES (2) | ES2585806T3 (sr) |
| HR (2) | HRP20160781T1 (sr) |
| HU (2) | HUE028650T2 (sr) |
| IL (1) | IL219234A (sr) |
| JO (2) | JO3267B1 (sr) |
| LT (1) | LT3093291T (sr) |
| ME (2) | ME02437B (sr) |
| MX (1) | MX2012004753A (sr) |
| NI (1) | NI201200062A (sr) |
| NZ (1) | NZ599629A (sr) |
| PE (1) | PE20110404A1 (sr) |
| PH (1) | PH12012500796A1 (sr) |
| PL (2) | PL2491038T3 (sr) |
| PT (2) | PT3093291T (sr) |
| RS (2) | RS54945B1 (sr) |
| SI (2) | SI2491038T1 (sr) |
| SM (2) | SMT201900392T1 (sr) |
| TR (1) | TR201910327T4 (sr) |
| TW (1) | TWI481613B (sr) |
| UA (1) | UA107812C2 (sr) |
| UY (1) | UY32966A (sr) |
| WO (1) | WO2011050198A1 (sr) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME02437B (me) | 2009-10-23 | 2016-09-20 | Janssen Pharmaceutica Nv | Disupstituirani oktahidropirolo[3,4-c]piroli kao modulatori oreksin receptora |
| US9586962B2 (en) * | 2011-04-20 | 2017-03-07 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators |
| US8501768B2 (en) * | 2011-05-17 | 2013-08-06 | Hoffmann-La Roche Inc. | Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds |
| DK2776430T3 (en) | 2011-11-08 | 2016-05-09 | Actelion Pharmaceuticals Ltd | 2- (1,2,3-triazol-2-yl) benzamide and 3- (1,2,3-triazol-2-yl) PICOLINAMIDDERIVATER AS orexin receptor antagonists |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| BR112014019426A8 (pt) | 2012-02-07 | 2017-07-11 | Eolas Therapeutics Inc | Prolinas/ piperidinas substituídas como antagonistas do receptor de orexina |
| TWI510481B (zh) | 2012-06-04 | 2015-12-01 | Actelion Pharmaceuticals Ltd | 苯并咪唑脯胺酸衍生物 |
| EP3584246A1 (en) | 2012-08-16 | 2019-12-25 | The Scripps Research Institute | Novel kappa opioid ligands |
| MX2015004638A (es) | 2012-10-10 | 2015-07-14 | Actelion Pharmaceuticals Ltd | Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-) aril]-[2-meta bi-(hetero-) aril)-pirrolidin-1-il]-metanona. |
| CN103012293A (zh) * | 2012-12-13 | 2013-04-03 | 同济大学 | 一种抗失眠药物mk-4305中间体的合成方法 |
| JP2016510810A (ja) | 2013-03-12 | 2016-04-11 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | オレキシン受容体アンタゴニストとしてのアゼチジンアミド誘導体 |
| TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代2-氮雜雙環類及其作為食慾素受體調控劑之用途 |
| TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
| TW201444821A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代之哌啶化合物及其作為食慾素受體調節劑之用途 |
| JP6647592B2 (ja) * | 2013-07-03 | 2020-02-14 | ルンドベック ラ ホーヤ リサーチ センター,インク. | ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用 |
| LT3077391T (lt) | 2013-12-04 | 2018-10-25 | Idorsia Pharmaceuticals Ltd | Benzimidazolo prolino darinių panaudojimas |
| WO2016020403A1 (en) * | 2014-08-04 | 2016-02-11 | Sandoz Ag | Preparation of a benzoic acid derivative and its use for the preparation of suvorexant |
| AR101558A1 (es) | 2014-08-13 | 2016-12-28 | Eolas Therapeutics Inc | Difluoropirrolidinas como moduladores del receptor de orexina |
| KR102455043B1 (ko) | 2014-09-11 | 2022-10-13 | 얀센 파마슈티카 엔.브이. | 치환된 2-아자바이사이클 및 오렉신 수용체 조절제로서의 이의 용도 |
| CN106349228B (zh) | 2015-07-17 | 2019-07-09 | 广东东阳光药业有限公司 | 取代的喹唑啉酮类化合物及其制备方法和用途 |
| CN106749269B (zh) * | 2015-11-23 | 2019-01-04 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物及其用途 |
| WO2017088731A1 (zh) * | 2015-11-24 | 2017-06-01 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物及其用途 |
| AU2017217931B2 (en) | 2016-02-12 | 2020-10-22 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
| IL288321B2 (en) * | 2016-03-10 | 2025-08-01 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
| WO2017197192A1 (en) | 2016-05-12 | 2017-11-16 | Abide Therapeutics, Inc. | Spirocycle compounds and methods of making and using same |
| CN105949203B (zh) * | 2016-05-24 | 2018-07-13 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物及其使用方法和用途 |
| CN107759620B (zh) * | 2016-08-16 | 2021-11-12 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物及其使用方法和用途 |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| CN108299437B (zh) * | 2017-01-13 | 2022-07-08 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物及其用途 |
| GB201702174D0 (en) * | 2017-02-09 | 2017-03-29 | Benevolentai Bio Ltd | Orexin receptor antagonists |
| CN110612291B (zh) | 2017-05-03 | 2024-02-13 | 爱杜西亚药品有限公司 | 2-([1,2,3]三唑-2-基)-苯甲酸衍生物的制备 |
| GB201707504D0 (en) * | 2017-05-10 | 2017-06-21 | Benevolentai Bio Ltd | Orexin receptor antagonists |
| GB201707499D0 (en) * | 2017-05-10 | 2017-06-21 | Benevolentai Bio Ltd | Orexin receptor antagonists |
| CN111050765B (zh) | 2017-08-29 | 2024-01-02 | H.隆德贝克有限公司 | 螺环化合物及其制造和使用方法 |
| PE20200665A1 (es) | 2017-08-29 | 2020-06-11 | Lundbeck La Jolla Research Center Inc | Compuestos espirociclicos y sus metodos de preparacion y uso |
| WO2019063605A1 (en) | 2017-09-28 | 2019-04-04 | Boehringer Ingelheim International Gmbh | NOVEL N- (2,2-DIFLUOROETHYL) -N - [(PYRIMIDINYLAMINO) PROPANYL] ARYLCARBOXAMIDES |
| CN109988169B (zh) * | 2017-12-29 | 2022-02-01 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物及其用途 |
| CN109988171A (zh) * | 2017-12-29 | 2019-07-09 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物及其用途 |
| CN109988170B (zh) * | 2017-12-29 | 2022-04-26 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物及其用途 |
| GB201809295D0 (en) | 2018-06-06 | 2018-07-25 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| WO2020023723A1 (en) * | 2018-07-27 | 2020-01-30 | Icahn School Of Medicine At Mount Sinai | Method of treating aggression with orexin receptor antagonists |
| RS65638B1 (sr) * | 2018-11-14 | 2024-07-31 | Janssen Pharmaceutica Nv | Unapređene sintetičke metode pravljenja fuzionisanih heterocikličnih jedinjenja kao modulatora receptora oreksina |
| GB201818750D0 (en) | 2018-11-16 | 2019-01-02 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| CN112142713A (zh) * | 2019-06-27 | 2020-12-29 | 山东润博生物科技有限公司 | 一种咪草烟的合成方法 |
| JP7672386B2 (ja) * | 2019-08-07 | 2025-05-07 | ヤンセン ファーマシューティカ エヌ.ベー. | オレキシン受容体調節薬としての(2h-1,2,3-トリアゾール-2-イル)フェニル化合物の改善された合成方法 |
| CN112876480B (zh) * | 2019-11-29 | 2022-07-26 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物的晶型 |
| CN112876478B (zh) * | 2019-11-29 | 2022-07-26 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物的晶型 |
| CN112876481B (zh) * | 2019-11-29 | 2022-07-26 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物的晶型 |
| CN112876477B (zh) * | 2019-11-29 | 2022-07-26 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物的晶型 |
| CN112876479B (zh) * | 2019-11-29 | 2022-07-26 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物的晶型 |
| WO2022122009A1 (zh) * | 2020-12-11 | 2022-06-16 | 苏州晶云药物科技股份有限公司 | 吡咯类衍生化合物的晶型及其制备方法 |
| KR20230159482A (ko) * | 2021-03-16 | 2023-11-21 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 질소-함유 헤테로사이클릭 폴리사이클릭 화합물, 이의 제조방법 및 이의 용도 |
| CN114063673B (zh) * | 2021-11-09 | 2023-03-03 | 万华化学集团股份有限公司 | 一种反应釜温度控制方法、系统及存储介质 |
| CN116217593B (zh) * | 2021-12-02 | 2025-05-09 | 江苏恩华药业股份有限公司 | 一种八氢吡咯并[3,4-c]吡咯甲基酮衍生物及其应用 |
| WO2023163964A1 (en) | 2022-02-24 | 2023-08-31 | Teva Czech Industries S.R.O. | Solid state forms of seltorexant |
| WO2023180556A1 (en) | 2022-03-24 | 2023-09-28 | Janssen Pharmaceutica Nv | Methods for treating agitation in subjects with mild cognitive impairment or major neurocognition disorder |
| CA3262219A1 (en) * | 2022-07-15 | 2024-01-18 | Biogen Ma Inc. | EMOPAMIL-BINDING PROTEIN (EBP) INHIBITORS AND THEIR USES |
| TW202416988A (zh) * | 2022-09-14 | 2024-05-01 | 大陸商江蘇豪森藥業集團有限公司 | 含氮雜環的多環化合物的游離鹼晶型及其製備方法 |
| JP7796892B2 (ja) * | 2022-11-23 | 2026-01-09 | チアンスー エヌエイチダブリュエー ファーマシューティカル カンパニー リミテッド | 二置換オクタヒドロピロロ[3,4-c]ピロールメチルケトン誘導体及びその使用 |
| EP4635949A1 (en) * | 2022-12-12 | 2025-10-22 | Jiangsu NHWA Pharmaceutical Co., Ltd | Substituted tetrahydrocyclopentyl[c]pyrrole derivative, preparation method, intermediate and use thereof |
| WO2024189472A1 (en) | 2023-03-14 | 2024-09-19 | Janssen Pharmaceutica Nv | Improved synthetic methods of making substituted pyrimidine intermediates for synthesis of orexin receptor modulators |
| WO2025003991A1 (en) | 2023-06-29 | 2025-01-02 | Janssen Pharmaceutica Nv | Method of treating depression using seltorexant |
| WO2025162233A1 (zh) * | 2024-01-29 | 2025-08-07 | 成都康弘药业集团股份有限公司 | 食欲素受体调节剂及其制备方法和用途 |
| WO2025242852A1 (en) | 2024-05-24 | 2025-11-27 | Janssen Pharmaceutica Nv | Seltorexant for use in treating major depressive disorder with insomnia symptoms |
| CN118580243B (zh) * | 2024-08-07 | 2025-01-03 | 艾斯拓康生物医药(天津)有限公司 | 一类含氮并环化合物及其制备方法和应用 |
| CN119039301B (zh) * | 2024-10-31 | 2025-09-02 | 江苏豪森药业集团有限公司 | 一种含氮杂环的多环化合物晶型ⅰ的制备方法 |
Family Cites Families (152)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7503310A (nl) | 1975-03-20 | 1976-09-22 | Philips Nv | Verbindingen met antidepressieve werking. |
| GB1526331A (en) | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| AU6153096A (en) | 1995-06-06 | 1996-12-24 | Abbott Laboratories | Quinolizinone type compounds |
| GB9519563D0 (en) | 1995-09-26 | 1995-11-29 | Merck Sharp & Dohme | Therapeutic agents |
| AU3555200A (en) | 1999-03-17 | 2000-10-04 | F. Hoffmann-La Roche Ag | Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators |
| US6375897B1 (en) | 2000-02-14 | 2002-04-23 | Ansys Technologies, Inc. | Urine collection cup |
| MY137020A (en) | 2000-04-27 | 2008-12-31 | Abbott Lab | Diazabicyclic central nervous system active agents |
| US6809105B2 (en) | 2000-04-27 | 2004-10-26 | Abbott Laboratories | Diazabicyclic central nervous system active agents |
| CA2408343A1 (en) | 2000-05-11 | 2002-11-07 | Banyu Pharmaceutical Co., Ltd. | N-acyltetrahydroisoquinoline derivatives |
| SE0100326D0 (sv) | 2001-02-02 | 2001-02-02 | Astrazeneca Ab | New compounds |
| WO2002070527A1 (en) | 2001-03-02 | 2002-09-12 | Akzo Nobel N.V. | Mass-selective purification of organometallics |
| EP1368354A1 (en) | 2001-03-07 | 2003-12-10 | Pfizer Products Inc. | Modulators of chemokine receptor activity |
| ES2266549T3 (es) | 2001-06-28 | 2007-03-01 | Smithkline Beecham Plc | Derivados de n-aroil-amina ciclicos como antagonistas del receptor de orexina. |
| US6455722B1 (en) | 2001-06-29 | 2002-09-24 | Pabu Services, Inc. | Process for the production of pentaerythritol phosphate alcohol |
| GB2383315B (en) | 2001-12-18 | 2005-04-06 | Christopher Donald Clarke | Vehicle imaging system |
| GB0130341D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| DE10226943A1 (de) | 2002-06-17 | 2004-01-08 | Bayer Ag | Phenylaminopyrimidine und ihre Verwendung |
| WO2004004733A1 (en) * | 2002-07-09 | 2004-01-15 | Actelion Pharmaceuticals Ltd. | 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives |
| RU2334735C2 (ru) | 2002-10-11 | 2008-09-27 | Актелион Фармасьютиклз Лтд. | Производные сульфониламиноуксусной кислоты и их применение в качестве антагонистов рецепторов орексина |
| GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| ES2327737T3 (es) | 2003-03-26 | 2009-11-03 | Actelion Pharmaceuticals Ltd. | Derivados de tetrahidroisoquinolil acetamida para uso como antagonistas de receptores de orexina. |
| WO2004096780A1 (en) | 2003-04-28 | 2004-11-11 | Actelion Pharmaceuticals Ltd | Quinoxalinone-3- one derivatives as orexin receptor antagonists |
| US20040242641A1 (en) | 2003-05-27 | 2004-12-02 | Buckley Michael J. | (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent |
| WO2005005439A1 (en) | 2003-07-09 | 2005-01-20 | Suven Life Sciences Limited | Benzothiazino indoles |
| TW200507850A (en) | 2003-07-25 | 2005-03-01 | Kyowa Hakko Kogyo Kk | Pharmaceutical composition |
| WO2005023231A1 (en) | 2003-09-10 | 2005-03-17 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Polypyrimidine tract binding protein promotes insulin secretory granule biogenesis |
| US7399765B2 (en) | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| US20050065178A1 (en) | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
| DK1691811T3 (da) | 2003-12-11 | 2014-10-20 | Sunovion Pharmaceuticals Inc | Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression |
| HUP0400405A3 (en) | 2004-02-10 | 2009-03-30 | Sanofi Synthelabo | Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
| HRP20150371T1 (hr) | 2004-03-01 | 2015-05-08 | Actelion Pharmaceuticals Ltd. | Supstituirani derivati 1,2,3,4-tetrahidroizokinolina |
| AU2005219438B2 (en) | 2004-03-03 | 2011-02-17 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
| US7435831B2 (en) | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
| EP1778688A1 (en) | 2004-07-22 | 2007-05-02 | Glaxo Group Limited | Antibacterial agents |
| US7229996B2 (en) | 2004-07-22 | 2007-06-12 | Cumbre Pharmaceuticals Inc. | Rifamycin derivatives |
| FR2874011B1 (fr) | 2004-08-03 | 2007-06-15 | Sanofi Synthelabo | Derives de sulfonamides, leur preparation et leur application en therapeutique |
| JP2008519078A (ja) | 2004-11-04 | 2008-06-05 | ニューロゲン コーポレイション | Cb1拮抗薬としてのアリールアルキル尿素類 |
| WO2006056848A1 (en) | 2004-11-24 | 2006-06-01 | Pfizer Limited | Octahydropyrrolo[3,4-c]pyrrole derivatives |
| DE102004061344A1 (de) | 2004-12-20 | 2006-07-06 | Siemens Ag | Verfahren zur sicheren Auslegung eines Systems, zugehörige Systemkomponente und Software |
| RU2007146444A (ru) | 2005-05-13 | 2009-06-20 | Лексикон Фармасьютикалз, Инк. (Us) | Полициклические соединения и способы их применения |
| US20060258691A1 (en) | 2005-05-13 | 2006-11-16 | Joseph Barbosa | Methods and compositions for improving cognition |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| US20080175795A1 (en) | 2005-06-30 | 2008-07-24 | Bexel Pharmaceuticals, Inc. | Novel derivatives of amino acids for treatment of obesity and related disorders |
| GB0514018D0 (en) | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
| AU2006282955A1 (en) * | 2005-08-26 | 2007-03-01 | Merck & Co., Inc. | Diazaspirodecane orexin receptor antagonists |
| FR2896798A1 (fr) | 2006-01-27 | 2007-08-03 | Sanofi Aventis Sa | Derives de sulfonamides, leur preparation et leur application en therapeutique |
| FR2896799B1 (fr) | 2006-02-02 | 2008-03-28 | Sanofi Aventis Sa | Derives de sulfonamides, leur preparation et leur application en therapeutique |
| US7553836B2 (en) | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
| WO2007126934A2 (en) | 2006-03-29 | 2007-11-08 | Merck & Co., Inc. | Amidoethylthioether orexin receptor antagonists |
| JP2009531447A (ja) | 2006-03-29 | 2009-09-03 | メルク エンド カムパニー インコーポレーテッド | ジアゼパンオレキシン受容体アンタゴニスト |
| EP2013209B1 (en) | 2006-04-26 | 2011-01-19 | Actelion Pharmaceuticals Ltd. | Pyrazolo-tetrahydropyridine derivatives as orexin receptor antagonists |
| WO2007146761A2 (en) | 2006-06-12 | 2007-12-21 | Neurogen Corporation | Diaryl pyrimidinones and related compounds |
| WO2008008518A1 (en) | 2006-07-14 | 2008-01-17 | Merck & Co., Inc. | Substituted diazepan orexin receptor antagonists |
| CA2657623A1 (en) | 2006-07-14 | 2008-01-17 | Merck & Co., Inc. | Bridged diazepan orexin receptor antagonists |
| EP2049526A2 (en) | 2006-07-14 | 2009-04-22 | Merck & Co., Inc. | 2-substituted proline bis-amide orexin receptor antagonists |
| US7994336B2 (en) | 2006-08-15 | 2011-08-09 | Actelion Pharmaceuticals Ltd. | Azetidine compounds as orexin receptor antagonists |
| US20100029617A1 (en) | 2006-08-28 | 2010-02-04 | Actelion Pharmaceuticals Ltd. | 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulene derivatives as orexin receptor antagonists |
| EP2066674B1 (en) | 2006-09-18 | 2010-06-30 | F.Hoffmann-La Roche Ag | Octahydropyrrolo [3, 4-c] pyrrole derivatives and their use as antiviral agents |
| WO2008038251A2 (en) | 2006-09-29 | 2008-04-03 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.1.0]hexane derivatives |
| US20100105614A1 (en) | 2006-10-25 | 2010-04-29 | Somaxon Pharmaceuticals, Inc. | Ultra low dose doxepin and methods of using the same to treat sleep disorders |
| WO2008067121A2 (en) | 2006-11-07 | 2008-06-05 | Lexicon Pharmaceuticals, Inc. | Methods of treating cognitive impairment and dementia |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| US20110077200A1 (en) | 2006-12-06 | 2011-03-31 | Somaxon Pharmaceuticals, Inc. | Combination therapy using low-dose doxepin for the improvement of sleep |
| WO2008078291A1 (en) | 2006-12-22 | 2008-07-03 | Actelion Pharmaceuticals Ltd | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives |
| CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
| CN101687882A (zh) | 2007-04-25 | 2010-03-31 | 百时美施贵宝公司 | 非碱性黑色素浓集激素受体-1拮抗剂 |
| JP2010527924A (ja) | 2007-05-18 | 2010-08-19 | メルク・シャープ・エンド・ドーム・コーポレイション | オキソ架橋ジアゼパンオレキシン受容体アンタゴニスト |
| FR2918061B1 (fr) | 2007-06-28 | 2010-10-22 | Sanofi Aventis | Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique. |
| GB0712888D0 (en) | 2007-07-03 | 2007-08-15 | Glaxo Group Ltd | Novel compounds |
| AU2008272449A1 (en) | 2007-07-03 | 2009-01-08 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.3.0]octane compounds |
| EP2176258A1 (en) | 2007-07-03 | 2010-04-21 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| WO2009011775A1 (en) | 2007-07-13 | 2009-01-22 | Merck & Co., Inc. | Amidoethyl alkylamino orexin receptor antagonists |
| FR2918986B1 (fr) * | 2007-07-19 | 2009-09-04 | Sanofi Aventis Sa | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
| NZ583487A (en) | 2007-07-27 | 2011-09-30 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.3.0]octane derivatives |
| JP2010535171A (ja) | 2007-08-02 | 2010-11-18 | エフ.ホフマン−ラ ロシュ アーゲー | オレキシン受容体アンタゴニストとしてのモノアミド誘導体 |
| CN101778846B (zh) | 2007-08-15 | 2012-11-14 | 埃科特莱茵药品有限公司 | 作为食欲素拮抗剂的1,2-二酰氨基-乙烯衍生物 |
| JP2010540429A (ja) | 2007-09-24 | 2010-12-24 | アクテリオン ファーマシューティカルズ リミテッド | オレキシン受容体拮抗薬としてのピロリジン類及びピペリジン類 |
| JP2011502146A (ja) | 2007-10-29 | 2011-01-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 置換ジアゼパンオレキシン受容体アンタゴニスト |
| DE102007052177A1 (de) | 2007-10-30 | 2009-05-07 | Novega Produktionssysteme Gmbh | Ortungsbake |
| EP2058001A1 (en) | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Enhancement of immunogenicity of antigens |
| US8003649B2 (en) | 2007-12-21 | 2011-08-23 | Astrazeneca Ab | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 |
| WO2009080533A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Heteroaryl derivatives as orexin receptor antagonists |
| GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
| KR20110022631A (ko) | 2008-05-27 | 2011-03-07 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 수면 장애 및 다른 장애를 치료하기 위한 방법 및 조성물 |
| BRPI0916657A2 (pt) | 2008-07-29 | 2019-03-26 | F.Hoffmann-La Roche Ag | pirrolidin-3-ilmetil-amina como antagonistas de orexina |
| AR072899A1 (es) | 2008-08-07 | 2010-09-29 | Merck Sharp & Dohme | Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad. |
| US20100267730A1 (en) | 2008-10-09 | 2010-10-21 | Giuseppe Alvaro | Novel compounds |
| US8093255B2 (en) | 2008-10-09 | 2012-01-10 | Glaxo Group Limited | Imidazo[1,2-A]pyrimidines as orexin receptor antagonists |
| US8129384B2 (en) | 2008-10-09 | 2012-03-06 | Glaxo Group Limited | Imidazo[1,2-a]pyrazines as orexin receptor antagonists |
| AU2009307913A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
| WO2010048014A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,4-disubstituted pyrrolidine orexin receptor antagonists |
| EP2348846B1 (en) | 2008-10-21 | 2013-08-28 | Merck Sharp & Dohme Corp. | Disubstituted azepan orexin receptor antagonists |
| CA2739916A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
| AU2009307920A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,3-disubstituted piperidine orexin receptor antagonists |
| WO2010048013A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted morpholine orexin receptor antagonists |
| JP5635991B2 (ja) | 2008-10-30 | 2014-12-03 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | イソニコチンアミドオレキシン受容体アンタゴニスト |
| US8703770B2 (en) | 2008-10-30 | 2014-04-22 | Merck Sharp & Dohme Corp. | Pyridazine carboxamide orexin receptor antagonists |
| US8399494B2 (en) | 2008-10-30 | 2013-03-19 | Merck Sharp & Dohme Corp. | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists |
| JP2012509912A (ja) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | 新規の化合物 |
| EP2358711A1 (en) | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| JP2012509911A (ja) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | 新規の化合物 |
| CA2745433A1 (en) | 2008-12-02 | 2010-06-10 | Glaxo Group Ltd. | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof |
| UY32276A (es) | 2008-12-02 | 2010-05-31 | Glaxo Group Ltd | Derivados de n-{[1s,4s,6s)-3-(2-piridinilcarbonil)-3-azabiciclo[4.1.0]hept-4-il}metil}-2heteroarilamina y uso de los mismos |
| GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
| US20100214135A1 (en) | 2009-02-26 | 2010-08-26 | Microsoft Corporation | Dynamic rear-projected user interface |
| SG175026A1 (en) | 2009-04-24 | 2011-11-28 | Glaxo Group Ltd | 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists |
| US20120149711A1 (en) | 2009-08-24 | 2012-06-14 | Glaxo Group Limited | Piperidine derivatives used as orexin antagonists |
| US20120149723A1 (en) | 2009-08-24 | 2012-06-14 | Romano Di Fabio | 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder |
| US8680275B2 (en) | 2009-10-23 | 2014-03-25 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| ME02437B (me) | 2009-10-23 | 2016-09-20 | Janssen Pharmaceutica Nv | Disupstituirani oktahidropirolo[3,4-c]piroli kao modulatori oreksin receptora |
| EP2491031B1 (en) | 2009-10-23 | 2013-08-07 | Janssen Pharmaceutica N.V. | Fused heterocyclic compounds as orexin receptor modulators |
| AU2010310596B2 (en) | 2009-10-24 | 2014-11-13 | Indiana University Research And Technology Corporation | Methods and compositions for panic disorders |
| TWI410630B (zh) | 2009-11-10 | 2013-10-01 | Ct Lab Inc | 一種用以治療與食慾素受體1、食慾素受體2、體抑素受體2或多巴胺d2l受體相關之疾病的方法和組合物 |
| RU2636589C2 (ru) | 2009-12-23 | 2017-11-24 | ДЖАСКО ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Аминопиримидиновые ингибиторы киназ |
| TW201307320A (zh) | 2010-12-17 | 2013-02-16 | 大正製藥股份有限公司 | 吡唑衍生物 |
| WO2012089607A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors |
| WO2012089606A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists |
| US9586962B2 (en) | 2011-04-20 | 2017-03-07 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators |
| JPWO2012153729A1 (ja) | 2011-05-10 | 2014-07-31 | 大正製薬株式会社 | ヘテロ芳香環誘導体 |
| JPWO2013005755A1 (ja) | 2011-07-05 | 2015-02-23 | 大正製薬株式会社 | メチルピペリジン誘導体 |
| EP2768305A4 (en) | 2011-10-21 | 2015-04-29 | Merck Sharp & Dohme | 2,5-DISUBSTITUTED THIOMORPHOLIN OREXINE RECEPTOR ANTAGONISTS |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| BR112014019426A8 (pt) | 2012-02-07 | 2017-07-11 | Eolas Therapeutics Inc | Prolinas/ piperidinas substituídas como antagonistas do receptor de orexina |
| US9493481B2 (en) | 2012-02-23 | 2016-11-15 | Vanderbilt University | Substituted 5-aminothieno[2,3—C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
| JP2014015452A (ja) | 2012-06-15 | 2014-01-30 | Taisho Pharmaceutical Co Ltd | ピラゾール誘導体を含有する医薬 |
| IN2014DN10490A (sr) | 2012-06-15 | 2015-08-21 | Taisho Pharmaceutical Co Ltd | |
| HK1203197A1 (en) | 2012-06-15 | 2015-10-23 | Taisho Pharmaceutical Co., Ltd. | Branched chain alkyl heteroaromatic ring derivative |
| JP2014111586A (ja) | 2012-11-09 | 2014-06-19 | Taisho Pharmaceutical Co Ltd | ヘテロ芳香環誘導体を含有する医薬 |
| EP2925321A4 (en) | 2012-11-27 | 2016-04-27 | Merck Sharp & Dohme | 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists |
| JP2016028017A (ja) | 2012-12-13 | 2016-02-25 | 大正製薬株式会社 | フッ素置換ピペリジン化合物 |
| JP2014141480A (ja) | 2012-12-28 | 2014-08-07 | Taisho Pharmaceutical Co Ltd | メチルピペリジン誘導体を含有する医薬 |
| TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代2-氮雜雙環類及其作為食慾素受體調控劑之用途 |
| WO2015018027A1 (en) | 2013-08-08 | 2015-02-12 | Merck Sharp & Dohme Corp. | Thiazole orexin receptor antagonists |
| IL246002B2 (en) | 2013-12-03 | 2024-11-01 | Intra Cellular Therapies Inc | Converted compounds of gamma-carboline fused with heterocycles for use in the treatment of residual symptoms of psychosis and a long-acting injectable preparation containing these compounds in a matrix |
| US9586934B2 (en) | 2013-12-09 | 2017-03-07 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-4-methyl orexin receptor antagonists |
| JP5930010B2 (ja) | 2013-12-13 | 2016-06-08 | 大正製薬株式会社 | ヘテロ芳香環メチル環状アミン誘導体を含有する医薬 |
| JP2015131802A (ja) | 2013-12-13 | 2015-07-23 | 大正製薬株式会社 | 分岐鎖アルキルヘテロ芳香環誘導体を含有する医薬 |
| WO2015095108A1 (en) | 2013-12-18 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thioether-piperidinyl orexin receptor antagonists |
| WO2015123355A1 (en) | 2014-02-12 | 2015-08-20 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| JP2017100950A (ja) | 2014-04-04 | 2017-06-08 | 大正製薬株式会社 | オキソ複素環誘導体 |
| JP2017100951A (ja) | 2014-04-04 | 2017-06-08 | 大正製薬株式会社 | オキサゾリジノン及びオキサジナノン誘導体 |
| WO2015180060A1 (zh) | 2014-05-28 | 2015-12-03 | 杭州普晒医药科技有限公司 | 一种二氮杂环庚烷化合物的盐及其晶型与无定型物 |
| AR101558A1 (es) | 2014-08-13 | 2016-12-28 | Eolas Therapeutics Inc | Difluoropirrolidinas como moduladores del receptor de orexina |
| US20160051533A1 (en) | 2014-08-20 | 2016-02-25 | Ladd Research LLC | Diagnosis and pharmacological treatment of seasonal affective disorder and symptoms of seasonality |
| GB201415569D0 (en) | 2014-09-03 | 2014-10-15 | C4X Discovery Ltd | Therapeutic Compounds |
| CN106349228B (zh) | 2015-07-17 | 2019-07-09 | 广东东阳光药业有限公司 | 取代的喹唑啉酮类化合物及其制备方法和用途 |
| GB201601703D0 (en) | 2016-01-29 | 2016-03-16 | C4X Discovery Ltd | Therapeutic compounds |
| IL288321B2 (en) | 2016-03-10 | 2025-08-01 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
| WO2020023723A1 (en) | 2018-07-27 | 2020-01-30 | Icahn School Of Medicine At Mount Sinai | Method of treating aggression with orexin receptor antagonists |
| GB201820458D0 (en) | 2018-12-14 | 2019-01-30 | Heptares Therapeutics Ltd | Ox1 antagonists |
-
2010
- 2010-10-21 ME MEP-2016-135A patent/ME02437B/me unknown
- 2010-10-21 SM SM20190392T patent/SMT201900392T1/it unknown
- 2010-10-21 JO JOP/2010/0362A patent/JO3267B1/ar active
- 2010-10-21 CA CA2778484A patent/CA2778484C/en active Active
- 2010-10-21 RS RS20160501A patent/RS54945B1/sr unknown
- 2010-10-21 NZ NZ599629A patent/NZ599629A/en unknown
- 2010-10-21 RS RS20190878A patent/RS59004B1/sr unknown
- 2010-10-21 ME MEP-2019-199A patent/ME03452B/me unknown
- 2010-10-21 KR KR1020127013101A patent/KR20120105449A/ko not_active Withdrawn
- 2010-10-21 EP EP16163733.5A patent/EP3093291B1/en active Active
- 2010-10-21 KR KR1020177034281A patent/KR101859409B1/ko active Active
- 2010-10-21 HR HRP20160781TT patent/HRP20160781T1/hr unknown
- 2010-10-21 HU HUE10773477A patent/HUE028650T2/en unknown
- 2010-10-21 PT PT16163733T patent/PT3093291T/pt unknown
- 2010-10-21 CN CN201080058816.XA patent/CN102781942B/zh active Active
- 2010-10-21 TR TR2019/10327T patent/TR201910327T4/tr unknown
- 2010-10-21 JP JP2012535384A patent/JP5759470B2/ja active Active
- 2010-10-21 DK DK16163733.5T patent/DK3093291T3/da active
- 2010-10-21 PL PL10773477.4T patent/PL2491038T3/pl unknown
- 2010-10-21 KR KR1020177034279A patent/KR101859400B1/ko active Active
- 2010-10-21 EP EP10773477.4A patent/EP2491038B1/en active Active
- 2010-10-21 BR BR112012010820-4A patent/BR112012010820B1/pt active IP Right Grant
- 2010-10-21 US US16/391,791 patent/USRE48841E1/en active Active
- 2010-10-21 WO PCT/US2010/053606 patent/WO2011050198A1/en not_active Ceased
- 2010-10-21 ES ES10773477.4T patent/ES2585806T3/es active Active
- 2010-10-21 UA UAA201206182A patent/UA107812C2/ru unknown
- 2010-10-21 SI SI201031214A patent/SI2491038T1/sl unknown
- 2010-10-21 AU AU2010310595A patent/AU2010310595B2/en active Active
- 2010-10-21 EA EA201270591A patent/EA022766B1/ru unknown
- 2010-10-21 DK DK10773477.4T patent/DK2491038T3/da active
- 2010-10-21 PL PL16163733T patent/PL3093291T3/pl unknown
- 2010-10-21 MX MX2012004753A patent/MX2012004753A/es active IP Right Grant
- 2010-10-21 PH PH1/2012/500796A patent/PH12012500796A1/en unknown
- 2010-10-21 ES ES16163733T patent/ES2735411T3/es active Active
- 2010-10-21 PT PT107734774T patent/PT2491038T/pt unknown
- 2010-10-21 US US13/503,231 patent/US8653263B2/en not_active Ceased
- 2010-10-21 SI SI201031898T patent/SI3093291T1/sl unknown
- 2010-10-21 HU HUE16163733A patent/HUE043962T2/hu unknown
- 2010-10-21 EP EP19172579.5A patent/EP3581575A1/en active Pending
- 2010-10-21 LT LTEP16163733.5T patent/LT3093291T/lt unknown
- 2010-10-22 CL CL2010001162A patent/CL2010001162A1/es unknown
- 2010-10-22 TW TW099136022A patent/TWI481613B/zh active
- 2010-10-22 PE PE2010001000A patent/PE20110404A1/es active IP Right Grant
- 2010-10-22 AR ARP100103874A patent/AR078731A1/es active IP Right Grant
- 2010-10-25 UY UY0001032966A patent/UY32966A/es active IP Right Grant
-
2012
- 2012-04-17 IL IL219234A patent/IL219234A/en active IP Right Grant
- 2012-04-20 NI NI201200062A patent/NI201200062A/es unknown
- 2012-05-11 CO CO12077916A patent/CO6541572A2/es unknown
- 2012-05-17 EC ECSP12011908 patent/ECSP12011908A/es unknown
- 2012-05-23 CR CR20120273A patent/CR20120273A/es unknown
-
2013
- 2013-12-23 US US14/138,941 patent/US9079911B2/en active Active
-
2015
- 2015-06-09 US US14/734,225 patent/US20150335651A1/en not_active Abandoned
- 2015-10-13 AU AU2015242975A patent/AU2015242975B2/en active Active
-
2016
- 2016-07-05 CY CY20161100629T patent/CY1117743T1/el unknown
- 2016-07-05 SM SM201600216T patent/SMT201600216B/it unknown
-
2017
- 2017-01-24 US US15/413,965 patent/US20170129901A1/en not_active Abandoned
-
2018
- 2018-03-14 JO JOP/2018/0019A patent/JOP20180019B1/ar active
-
2019
- 2019-03-07 AR ARP190100557A patent/AR114667A2/es unknown
- 2019-07-05 HR HRP20191220TT patent/HRP20191220T1/hr unknown
- 2019-07-26 CY CY20191100794T patent/CY1121848T1/el unknown
- 2019-10-15 US US16/601,832 patent/US11059828B2/en active Active
-
2021
- 2021-07-09 US US17/372,168 patent/US11667644B2/en active Active
-
2023
- 2023-06-02 US US18/327,990 patent/US12378254B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS59004B1 (sr) | Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora | |
| RS50154B (sr) | Aparat za ispitivanje i pronalaženje oštećenja u delovima putem endoskopije | |
| JP6118736B2 (ja) | 内視鏡検査によって部品上の欠陥を探索するための装置 | |
| US5115136A (en) | Ultraviolet remote visual inspection system | |
| RU2626966C2 (ru) | Устройство для отображения внутренней поверхности полого пространства в изделии | |
| RU2359296C2 (ru) | Эндоскоп с ультрафиолетовым освещением (варианты) | |
| EP2818908B1 (en) | Endoscope system | |
| WO2005096059A1 (ja) | 観察装置および蛍光観察装置 | |
| JPH02193007A (ja) | 管または中ぐり穴の内部輪郭の光学検査用装置 | |
| US5608520A (en) | Plasma emission spectroscopy method of tumor therapy | |
| US20030117617A1 (en) | Bore scope with test light | |
| KR20030033177A (ko) | 형광 내시경 장치 및 그 장치를 이용한 진단부위 조상 방법 | |
| CN114246543B (zh) | 用于宫颈癌早期诊断的移动式阴道镜装置 | |
| KR101887033B1 (ko) | 치아 구조/기능 영상을 위한 복합영상장치 | |
| JPH03231622A (ja) | 内視鏡装置 | |
| RU2528856C2 (ru) | Стенд и способ контроля посредством магнитной дефектоскопии вала газотурбинного двигателя | |
| SALIY et al. | Practice of Visual Diagnostics Using Endoscopes | |
| US3733138A (en) | Optical system for inspection of a cavity | |
| RU226390U1 (ru) | Устройство для неразрушающего поиска дефектов скрытых деталей | |
| KR20090098393A (ko) | 관체 내부 관측용 광학기기 | |
| KR20070006043A (ko) | 구멍 내벽 검사 장치 | |
| RU2377544C1 (ru) | Рентгенооптический эндоскоп | |
| JP2001059941A (ja) | ファイバースコープシステム | |
| JPH0526566Y2 (sr) | ||
| CN114660079A (zh) | 一种实现管径缺陷检测的侧视观察方法 |